Per the 2018 ASCO/CAP criteria, HER2-positive breast cancer (IHC 3+ or 2+/ISH+) is eligible for established anti-HER2 therapies, whereas true HER2-0 (no staining) is not, outside trials. This evidence concerns the gene ERBB2 and breast carcinoma.